Celyad Oncology SA News - CYAD

CELYAD S.A.: Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immuno...

Celyad grants an exclusive license to ONO for the development and commercialization of Celyad's unique allogeneic NKR-2 T-cell in Japan...

CELYAD S.A.: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy

A statistically-significant difference on the primary endpoint was not reached; however, a positive trend was seen across all treatment...

Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-Deficient CAR T-Cells

MONT-SAINT-GUIBERT, Belgium, March 02, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD...

Celyad Successfully Completes Safety Follow-Up of the Second Dose Level of Patients in Its NKR-2 Trial and Enrolls First Pati...

The trial is a dose escalation study evaluating safety and feasibility of T-cell Natural Killer Receptor...

Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination...

MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD...

Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs

MONT-SAINT-GUIBERT, Belgium, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD...

Celyad Announces 2016 Financial Calendar

MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD...

Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial

No dose limiting toxicity related to the investigational treatment reported at 30 days post treatment of the...

Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference

MONT-SAINT-GUIBERT, Belgium, Dec. 23, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Celyad Oncology SA (CYAD)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CYAD News

CELYAD S.A.: Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immuno...

CELYAD S.A.: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy

Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-Deficient CAR T-Cells

Celyad Successfully Completes Safety Follow-Up of the Second Dose Level of Patients in Its NKR-2 Trial and Enrolls First Pati...

Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination...

Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs

Celyad Announces 2016 Financial Calendar

Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial

Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference

CYAD Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Celyad Oncology SA (CYAD) News

Celyad Oncology SA (CYAD)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CYAD News

CELYAD S.A.: Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immuno...

CELYAD S.A.: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy

Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-Deficient CAR T-Cells

Celyad Successfully Completes Safety Follow-Up of the Second Dose Level of Patients in Its NKR-2 Trial and Enrolls First Pati...

Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination...

Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs

Celyad Announces 2016 Financial Calendar

Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial

Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference

CYAD Discussion

Your Recent History